browse Browse

pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
88a6ffbd-8400-46ef-af8c-de6159486b34
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-20 15:37:51
Income (reported)
—
Expenses (reported)
$3,930,000
Expenses method
A
Filing document
Open on lda.senate.gov
Registrant (lobbying firm)

NOVARTIS

Federal Government Relations/Legislative Affairs

Contact
COURTNEY PIRON
Phone
+1 202-662-4364
Address
zip:20004, city:Washington, state:DC, street:801 Pennsylvania Avenue, NW Suite 700
Client

NOVARTIS

State
DC
Country
US
Government-entity client
false
Effective date
2010-12-07
Issues lobbied + lobbyists (7)

BUD — Budget/Appropriations

H.R. 5371: Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 Funding for FDA - FY 2026 Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act 2026 FY 2026 President's Budget Request Inflation Reduction Act of 2022 (P.L. 117-169) Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 Federal Budget Funding for National Institutes of Health - FY 2026 Appropriations H.R. 1: One Big Beautiful Bill Act (P.L. 119-21) FY 2027 President's Budget H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75)

Lobbyists:

Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE; White House Office

CPT — Copyright/Patent/Trademark

S. 43: Skinny Labels, Big Savings Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 2276/HR. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent eligibility policy issues H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) Restrictions on Intellectual Property Rights PTAB reform Patent fee policy issues

Lobbyists:

Government entities lobbied: Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); SENATE; U.S. Trade Representative (USTR)

HCR — Health Issues

Direct to Consumer Advertising 340B Drug Discount Program - Program Implementation & Oversight 340B PATIENTS Act of 2024 340B Drug Discount Program - RFI for SUSTAIN 340B Act HR. 5256 - 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act(340B ACCESS Act) To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program 340B drug discount program rebate and policy issues 340B rebate pilot program Accelerated Approval Breast Cancer Research H.R.3037, Access to Breast Cancer Diagnostic Act of 2025 S.1500, Access to Breast Cancer Diagnostic Act of 2025 Alternative Funding Programs Supply Chain Integrity and Traceability PBM Reform Modernizing and Ensuring PBM Accountability (MEPA) Act Coverage of Accelerated Approval Products Drug Benefit Design Orphan Drug Issues S. 1682/H.R.946: ORPHAN Cures Act S.932/H.R. 1262: Give Kids a Chance Act of 2025 Innovation in Pediatric Drugs Act S.864: HELP Copays Act Reimbursement and Coverage of Innovative Products Lower Costs, More Transparency Act Lower Costs, More Cures Act Medicare Part B Physician-Administered Products Patient Cost-Sharing and Smoothing Step Therapy Support of Patient Premiums and Cost-Sharing Obligations Value-based Contracting and Communications H.R. 2214: DRUG Act User fee policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Drug importation policy issues FDA regulatory approval authority policy issues Competition policy issues Clinical trial diversity policy issues Patient assistance program policy issues Drug shortages policy issues Artificial intelligence policy issues IRA price negotiation expansion policy issues Rare Pediatric Disease Priority Review Voucher program policies SUSTAIN RFI/discussion draft Most Favored Nation (MFN) policy Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Utilization management policies

Lobbyists:

Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Congressional Budget Office (CBO); Executive Office of the President (EOP); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE; Treasury, Dept of; U.S. Trade Representative (USTR); White House Office

MMM — Medicare/Medicaid

GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule H.R. 950: Saving Seniors Money on Prescriptions Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues S. 832/H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025 Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues H.R. 5391/S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act

Lobbyists:

Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE; White House Office

TRD — Trade (domestic/foreign)

Sec. 301 pharmaceutical tariffs US-UK Framework Agreement Tariff policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues International pharmaceutical pricing and reimbursement policy issues Supply chain policy issues China outbound investment policy issues US Swiss Trade Agreement US Trade Policy Sec. 232 pharmaceutical tariffs Pharmaceutical manufacturing policy and investment issues

Lobbyists:

Government entities lobbied: Commerce, Dept of (DOC); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); SENATE; Treasury, Dept of; U.S. Trade Representative (USTR); White House Office

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.